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Abstract: US health care reform includes an abbreviated pathway for follow-on biologics, also 
known as biosimilars, in an effort to speed up access to these complex therapeutics. However, 
a key patient safety challenge emerges from such an abbreviated pathway:  immunogenicity 
  reactions. Yet immunogenicity is notoriously difficult to predict, and even cooperative approaches 
in licensing between companies have resulted in patient safety concerns, injury, and death. 
Because approval pathways for follow-on forms do not involve cooperative disclosure of 
  methods and manufacturing processes by innovator companies and follow-on manufacturers, the 
potential for expanded immunogenicity must be taken into account from a risk   management and 
patient safety perspective. The US Institute of Safe Medication Practices (ISMP) has   principles 
of medication safety that have been applied in the past to high-risk drugs. We propose   adapting 
ISMP principles to follow-on biologic forms and creating systems approaches to warn, rapidly 
identify, and alert providers regarding this emerging patient safety risk. This type of system 
can be built upon and provide lessons learned as these new drug forms are developed and 
marketed more broadly.
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Introduction
The much-anticipated passage of US health care reform has created opportunities for 
improving quality and safety in health care.1 However, changes in public policy, like 
changes in the delivery system, have an impact on system function and may create 
new vulnerabilities despite quality and safety provisions in the law.
One key policy created by health care reform is a new pathway for approval of 
“follow-on biologics,” also known as “biosimilars.” This pathway, formally known 
as the Biologics Price Competition and Innovation Act (BPCIA) within the Patient 
Protection and Affordable Care Act reform law, would theoretically speed nonbranded 
forms of biotechnology-derived therapeutic protein products to market at lower prices, 
akin to the Hatch-Waxman Act that sped small molecule generic drug form develop-
ment and market entry.2
Yet original and copied biologic drugs have had safety challenges, primarily immu-
nogenicity, where the drug induces an unwanted immune reaction in the human body. 
Immunogenicity is generally unrecognized in clinical care as a safety vulnerability for 
patients and a drain on health care resources for patients who develop antidrug antibodies 
and no longer respond to therapy.3 However, with the passage of policy that incentiv-
izes follow-on drug forms, which have immunogenicity risks, health care safety leaders Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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should expressly note this potential and act to address them 
in dynamic assessment of local delivery systems.
Immunogenicity: branded forms
At the outset, therapeutic protein recombinant forms have 
immunogenicity potential because of their size, living cell-
based manufacture, and protein configuration, compared 
with small molecule, solid-chemical pills. Yet predicting 
immunogenicity is notoriously difficult.4   Immunogenicity 
appears related to a broad array of divergent factors, 
including the molecule’s structure, patient genetics, type of 
  biologic,   impurities, and other factors including the route of 
  administration and frequency of use.5
Compounding their difficulty to predict, immunogenic-
ity reactions can be clinically severe and present a major 
medical emergency,6 clearly necessitating patient safety 
system attention. For example, existing US Food and Drug 
Administration (FDA)-approved recombinant drug forms can 
lead to unrecognized immunogenicity and require long-term 
clinical surveillance to identify accurately.7
In addition, short-term data has revealed that immuno-
genicity of monoclonal antibodies in biologic therapeutics 
may have negative impacts on treatment response for condi-
tions such as inflammatory bowel disease, types of arthritis, 
multiple sclerosis, and Crohn’s disease.8 Long-term studies 
of immunogenicity of monoclonal antibodies that leads 
to antidrug antibody response are also associated with 
treatment discontinuance and higher disease activity with 
antidrug antibody formation in more than a quarter (28%) 
of patients over a 3-year period.8 Immunogenicity issues in 
long-term treatment using human recombinant interferon β   
for multiple sclerosis has also shown the potential to 
  negatively impact therapy.9
Yet the interferon β work also illustrates the challenges 
of prediction of immunogenicity effects. The frequency of 
immunogenicity and the magnitude of neutralizing antibody 
formation may differ among varying interferon β products. 
This further reifies the need for continuous and long-term 
  surveillance of patients utilizing therapeutic products to 
ensure complications arising from immunogenicity are 
adequately identified and addressed.
Immunogenicity: cooperative 
licensing
Beyond FDA-approved products, immunogenicity is 
a critical patient safety concern even when companies 
  cooperatively license to produce a biosimilar product. 
The case of Epogen (erythropoietin) licensing from a US 
  producer to a European Union (EU) manufacturing context 
is an important example.
Erythropoeitin is a naturally occurring human protein 
as well as a biologic drug that promotes red blood cell 
growth. In the late 1990s, Amgen licensed the exclusive 
rights to produce the drug to Johnson & Johnson in the EU 
(Eprex), while Amgen retained US production and sales 
(Epogen). Both purportedly used the same methodology to 
produce the drug.5 Johnson & Johnson made several, what it 
considered minor, manufacturing changes in its production 
of Eprex. After about 2 years, however, multiple patients 
taking Eprex in the EU developed a rejection reaction to 
the drug resulting in pure red cell aplasia, a severe and 
life-threatening condition where the bone marrow ceases 
to produce red blood cells. No such effect was observed in 
patients taking Epogen.
Investigation revealed that Eprex had a different immu-
nogenicity profile than Epogen, with patients developing 
antibodies to the new formulation.10 Although this alone was 
cause for alarm, beyond creating a rejection reaction to the 
drug, the new immunogenicity created antibodies against 
the patients’ own naturally occurring erythropoietin. This 
resulted in the patients’ immune systems attacking their 
own body’s erythropoietin, as well as a cross-reactivity 
response to other medicinal forms of the biologic beyond 
Eprex. The outcome was that patients could not produce red 
blood cells using their own or other biologic forms of the 
drug. Ultimately, severals patient died and others became 
permanently transfusion-dependent. A combination of high 
dose immunosuppressive therapy and renal transplantation 
has been required to treat many of these victims. The results 
of seemingly minor changes in the biologic had a tremendous 
negative clinical impact on these patients.
The clinical concerns over this event resulted in intensive 
investigation. Yet despite continuing research efforts, no 
clear conclusions have emerged. A wide array of theories 
has been offered, including different carbohydrate structures, 
route of administration, a change in the stabilizer, a change 
in the rubber stopper, and an aggregation of these and other 
factors.5 The debate and search continues for the etiology or 
etiologies underlying the severe reactions associated with 
the biologic.11
Follow-on biologics: emerging  
safety concerns
Though safety concerns regarding this incident have yet 
to be resolved, recent testing of an Epogen follow-on 
biologic product by Hospira Inc have begun in the US.12 Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Other companies have also announced plans to enter 
into the follow-on market. Thus, delivery systems may 
face these policy-created patient safety challenges sooner 
rather than later.
The interferon β, Epogen/Eprex, as well as other examples 
show the sensitive and complex nature of human reactivity to 
biologics.13 Importantly, the research, testing, and technol-
ogy supporting assessment of biologics were well known to 
regulatory authorities and industry and full product reviews 
had been performed. Yet despite this process, severe clinical 
problems resulted and have yet to be explained sufficiently. 
Indeed, even the same manufacturing entity may experience 
immunogenicity difficulties in their products when relatively 
minor conditions are changed.
Under health care reform, these challenges will likely 
be magnified. Through empowering the FDA to create 
an abbreviated approval pathway for biologic products, 
follow-on biologics will likely become a greater portion 
of the therapeutic arsenal to treat complex and co-morbid 
disease. Of particular concern is the lack of specific details 
regarding analytical, animal, and clinical data needed to 
support a designation of a biological product as being 
“biosimilar.” Given the presence of immunogenicity in 
patients both in short-term and long-term studies, careful 
consideration of the inherent limitations of supporting 
clinical trial data in detecting immunogenicity risks in 
patient populations needs to be taken into account. Indeed, 
there are challenges with assaying all therapeutic proteins, 
including innovator products. Because of their inherent 
complexity, simply assaying the protein is not sufficient 
to show comparability.
Beyond simple comparability, the possibility for 
“  interchangeability” classification under the abbreviated 
  pathway, which permits a biosimilar product to be substituted 
for the prescribed product, as small molecule generic products 
are substituted for brand name forms, may also lead to increased 
utilization of such products and subsequent incidence of 
immunogenicity. Issues with naming follow-on forms that do 
not specifically identify the manufacturer creates even greater 
patient safety risks under interchangeability designations.5
Immunogenicity may also become more common because 
the product “following on” the branded biologic will not be 
cooperatively licensed, nor will manufacturing methods be 
disclosed to the follow-on producer as in the Epogen/Eprex 
case. As such, there may be significant risk that such biologic 
product may create immunogenicity due to modification 
in manufacturing processes and other unforeseen changes 
compared to its original production.
Safety policy
Building on the experience with recombinant therapeutic 
products, patient safety advocates must be keenly aware 
that immunogenicity is a significant clinical safety issue that 
should be specifically noted and addressed. But further, the 
public policy favoring these products will create systems 
issues for health care delivery that require special patient 
safety consideration. Indeed, the need for attention is urgent: 
the potential presence of immunogenicity that is not part of 
the general knowledge or given much attention by safety 
advocates will be exacerbated by potentially increasing 
numbers of unexplained immune reactions under health care 
reform incentives.
To address this patient safety concern, follow-on biologic 
products should be added as a category to the US Institute of 
Safe Medication Practices (ISMP) “High-Alert Medications” 
because these are drugs for which “the consequences of an 
error are clearly more devastating to patients.”14 By doing so, 
the patient safety community will be alerted to the importance 
of monitoring these drug forms.
Once recognized as a high-alert medication, patient safety 
advocates and teams should consider using established ISMP 
tools to design safety systems to avoid preventable error 
with these medications as well as create systems resilient 
to its presence. Depending on the local health care delivery 
  infrastructure, system interventions improving access to 
information about these drugs should first be put into place. 
Warnings as to immunogenicity posted with the drug in 
the pharmacy, on physician order entry, and on dispens-
ing records should be prominently displayed and attached, 
and recurrent in-service training for provider teams should 
emphasize this adverse event potential. Further, consistent 
with provisions to engage patients as part of the patient 
safety team, patients who are taking follow-on biologic drugs 
should also be provided with layperson, understandable 
  information as part of informed consent, regarding the risks of 
  immunogenicity with follow-on biologics, and areas to assess 
that may provide early warnings of any   immunogenicity 
  reactions. Since the patient and caregivers are the last barrier 
to harm, it is especially important to engage them as members 
of the safety team and provide information to empower them 
to identify potential issues with these therapeutic forms. 
Of course, this latter should be sensitive to the patient and 
caregiver competency, ability, and wishes.
In addition, at least on the inpatient level, follow-on 
biologics access should be limited as other high-alert medi-
cations are. Use of a locked cabinet and signout forms with 
immunogenicity warnings in combination with education Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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can highlight the importance of immunogenicity risk to 
those who will dispense the drug at the pharmacy and on 
the hospital floors.
The use of auxiliary labels and automated alerts, if 
the local health IT infrastructure can accommodate it, for 
follow-on form warnings and patient safety redundancy 
can also be beneficial as a safety intervention. An auxil-
iary label that is amenable to immunogenicity warnings 
transmitted automatically to the physician who ordered 
the drug can also provide redundancy in clinical informa-
tion and potential risks associated with these drug forms. 
Taking a page from drug company direct to consumer 
advertising and use of the Internet,15 using mobile handset 
technology may be an appropriate system to employ for 
these warnings.
These efforts should be coupled with implementation of 
a robust patient surveillance system as a condition of FDA 
approval of all follow-on biologic products. Such a system 
could build upon previous reform policy proposals for off-
label promotion of orphan drugs that require manufacturers 
to submit a pharmacovigilance and risk   management plan.16 
Part of this plan should include provisions for monitoring 
and regular immunogenicity testing, which would   identify 
potential emerging adverse reactions and can avoid 
  immunogenicity-related ineffective treatment.
In addition, we believe that standardization of purchase 
and use of these products is essential. Facilities ordering 
  follow-on products should consider purchasing only one brand 
to provide rapid identification of the product that resulted in 
immunogenicity, or at the very least, have systems in place 
to clearly identify the company and version of the follow-on 
product purchased. Further, protocols in administration of 
follow-on products and express notation of immunogenicity 
potential should be put into place, relevant to the specific dis-
ease state. As well, clinical practice guidelines, US Preventive 
Services Task Force recommendations, UK National Institute 
for Health and Clinical Excellence, and other recognized 
therapeutic guidance sources should incorporate immune 
status as a regular assessment in these situations.
These policy approaches may require legislation, which 
may be difficult to drive forward. This emphasizes the need for 
cooperative approaches between patients, providers, and safety 
leaders. Key safety organizations can play a significant role 
without legislation through voluntary engagement in education 
and attention to immunogenicity concerns as outlined above. 
Key drug safety groups such as the Institute for Safe Medication 
Practices and American Pharmacists Association, patient 
safety organizations with provider and patient representation 
including the National Patient Safety Foundation and the WHO 
World Alliance for Patient Safety, and brand and generic 
pharmaceutical manufacturer organizations including the 
Pharmaceutical Research and   Manufacturers of America and 
Generic Pharmaceutical Association, as well as the   International 
Pharmaceutical   Federation and the European   Generics 
Association can create an alliance for follow-on   biologic 
safety, and should work jointly in   educational endeavors to 
inform the public regarding the need for   vigilance regarding 
follow-on biologics. Further, an umbrella entity of these 
organizations can work together with drug regulatory agencies 
in public–private partnerships to   leverage key knowledge from 
each to adopt, maintain, and update best practices in follow-on 
biologic safety.   Public–private partnerships have become 
important in addressing important health policy concerns,17 
and may have significant benefit for drug safety in this setting.   
A public–private, global health approach for safety of   follow-on 
biologics would also provide important lessons learned and 
proactive safety planning as these molecules become more 
integrated into treatment in emerging and developing country 
environments.
Conclusion
Addressing dynamic patient safety issues is difficult. In cases 
of immunogenicity and biologic drugs, limited scientific 
knowledge as to predictability, rare potential occurrence, 
but severe negative consequences if an adverse event occurs, 
create the perfect storm of system gaps that can align to 
allow significant harm to reach the patient. Furthermore, this 
potential is magnified by policy created to incentivize the 
production of follow-on drug forms but fails to adequately 
address extant patient safety risks. Beyond a focus on local 
systems and pathways of care, patient safety advocates and 
policymakers should take into account these challenges 
associated with new public policies. By doing so, they may 
be able to proactively design systems to avoid preventable 
error and be resilient to challenges created by biologics, their 
follow-on forms, and public policy that incentivizes their 
production and use.
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